In vivo CTL elicitation by heat shock protein fusion...

Details In vivo CTL elicitation by heat shock protein fusion... In vivo CTL elicitation by heat shock protein fusion...

2005-04-05

2005-04-05

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S184100, C424S185100, C424S190100, C424S192100, C424S193100, C424S194100, C424S197110, C424S234100, C424S246100, C424S248100, C424S201100

Reexamination Certificate

active

06875435

ABSTRACT:
The present invention relates to a method of inducing a CD8+CTL response to a molecule in an individual deficient in CD4+T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. In addition, the present invention relates to a composition characterized by a portion of an ATP biding domain of an hsp joined to a molecule.

REFERENCES:
patent: 4557931 (1985-12-01), Irie et al.
patent: 4716038 (1987-12-01), Standford et al.
patent: 4724144 (1988-02-01), Rook et al.
patent: 4918166 (1990-04-01), Kingsmen et al.
patent: 5114844 (1992-05-01), Cohen et al.
patent: 5504005 (1996-04-01), Bloom et al.
patent: 5580563 (1996-12-01), Tam et al.
patent: 6030618 (2000-02-01), Sirivastava
patent: 6335183 (2002-01-01), Young
patent: 6338952 (2002-01-01), Young
patent: 6403099 (2002-06-01), Rappuoli et al.
patent: 6455493 (2002-09-01), Wallen et al.
patent: 6482614 (2002-11-01), Young
patent: 6495347 (2002-12-01), Siegel et al.
patent: 0 262 710 (1987-09-01), None
patent: 0 322 990 (1989-07-01), None
patent: 2 251 186 (1992-07-01), None
patent: WO 8505034 (1985-11-01), None
patent: WO 8800974 (1988-02-01), None
patent: WO 8805823 (1988-08-01), None
patent: WO 8806591 (1988-09-01), None
patent: WO 8912455 (1989-12-01), None
patent: WO 9015873 (1990-12-01), None
patent: WO 9102542 (1991-06-01), None
patent: WO 9115572 (1991-10-01), None
patent: WO 9208484 (1992-05-01), None
patent: WO 9208488 (1992-05-01), None
patent: WO 9317712 (1992-09-01), None
patent: WO 9403208 (1994-02-01), None
patent: Wo 9429459 (1994-12-01), None
patent: WO 9524923 (1995-09-01), None
patent: WO 9531994 (1995-11-01), None
patent: WO 9610421 (1996-04-01), None
patent: WO 9706821 (1997-02-01), None
patent: WO 9726910 (1997-07-01), None
patent: WO 9823735 (1998-06-01), None
patent: WO 9835705 (1998-08-01), None
patent: WO 9907860 (1999-02-01), None
Geluk et al. J. Immunol. 1992, vol. 149, pp. 2864-2871.*
Ciupitu et al. J. Exp, Med. 1998, vol. 187, p. 685-691.*
Roman et al. Immunology 1996, vol. 88, pp. 487-492.*
Amadori, M., et al., “Chaperonin 10 o fMycobacterium tuberculosis Induces a Protective Immune Response to Foot-and-Mouth Disease Virus,” Arch Virol. 144:905-919 (1999).
Babbitt, et al., “Binding of Immunogenic Peptides to Ia Histocompatibility Molecules,” Nature 317:359-361 (1985).
Brett, et al., “Differential Pattern of T Cell Recognition of the 65-kDA Mycobacterial Antigen Following Immunization with the Whole Protein or Peptides,” Euro. J. Immunol. 19:1303-1310 (1989).
Chen, W., et al., “Human 60-kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System,” J. Immunol. 162:3212-3219 (1999).
Cox, et al., “Orientation of Epitopes Influences the Immunogenicity of Synthetic Peptide Dimers,” Euro. J. Immunol. 18:2015-2019 (1988).
Delmas, A., et al., “Studies of the Influence of Different Cross-Linking Reagents on the Immune Response against a B-Epitope,” Bioconjugate Chemistry 3(1):80-84 (1992).
Dintzis, R.Z., “Rational Design of Conjugate Vaccines,” Pediatric Research 32(4):376-385 (1992).
Engel, et al., “Generation of Antibodies Against Human hsp27 and Murine hsp25 by Immunization with a Chimeric Small Heat Shock Protein,” Biomed. Biochim. Acta 50:1065-1071 (1991).
Francis, et al., “Peptide Vaccines Based on Enhanced Immunogenicity of Peptide Epitopes Presented with T-Cell Determinants or Hepatitis B Core Protein,” Meth. Enzymol. 178:659-676 (1989).
Fyfe, et al., “Murine Immune Response to HIV-1 p24 Core Protein Following Subcutaneous, Intraperitoneal and Intravenous Immunization,” Immunology 74:467-472 (1991).
Gariepy, J., et al., “Vectorial Delivery of Macromolecules Into Cells Using Peptide-Based Vehicles,” Trends Biotechnol. 19(1):21-28 (2001).
Gelber, R.H., et al., “Vaccination With PureMycobacterium lepraeProteins InhibitsM. lepraeMultiplication in Mouse Footpads,” Infection and Immunity 62(10):4250-4255 (Oct. 1994).
Grange, J.M., et al., “Tuberculosis and Cancer: Parallels in Host Responses and Therapeutic Approaches?,” The Lancet 345:1350-1352 (1995).
Hawiger, J., “Noninvasive Intracellular Delivery of Functional Peptides and Proteins,” J. Curr. Opin. Chem. Biol. 3:89-94 (1999).
Horwitz, M.A., et al., “Protective Immunity Against Tuberculosis Induced by Vaccination With Major Extracellular Proteins ofMycobacterium tuberculosis,” Microbiology 92:1530-1534 (Feb. 1995).
Lehner, T., et al., “Heat Shock Proteins Generate ?-Chemokines Which Function as Innate Adjuvants Enhancing Adaptive Immunity,” Eur. J. Immunol. 30:594-603 (2000).
Lindgren, M., et al., “Cell-Penetrating Peptides,” TiPS 21(3):99-103 (Mar. 2000).
Matthews, R.C., et al., “Autoantibody to Heat-Shock Protein 90 Can Mediate Protection Against Systemic Candidosis,” Immunology 74:20-24 (1991).
Morris, M.C., et al., “Translocating Peptides and Proteins and Their Use for Gene Delivery,” Curr. Opin. Biotechnol. 11(5):461-466 (Oct. 2000).
Multhoff, G., et al., “The Role of Heat Shock Proteins in the Stimulation of an Immune Response,” Biol. Chem. 379:295-300 (Mar. 1998).
Myers, “Role of B Cell Antigen Processing and Presentation in the Humoral Immune Response,” FASEB J. 5:2547-2553 (1991).
Parker, “T-Cell Dependent B Cell Activation,” Annu. Rev. Immunol. 11:331-360 (1993).
Rost, B., “Twilight Zone of Protein Sequence Alignments,” Protein Engineering 12(2):85-94 (1999).
Schwarze, S.R., et al., “Protein Transduction: Unrestricted Delivery Into All Cells?,” Trends Cell Biol. 10(7):290-295 (Jul. 2000).
Townsend, et al., “Antigen Recognition by Class I-Restricted T Lymphocytes,” Ann. Rev. Immunol. 7:601-624 (1989).
Vogt, G., et al., “An Assessment of Amino Acid Exchange Matrices In Aligning Protein Sequences: The Twilight Zone Revisited,” J. Molec. Biol. 249:816-831 (1995).
Yewdell, et al., “The Binary Logic of Antigen Processing and Presentation to T Cells,” Cell 62:203-206 (1990).
Suzue, K. and Young, R.A., “Adjuvant-Free hsp70 Protein System Elicits Humoral and Cellular Immune Responses to HIV-1 p24,”J. Immunol. 156:873-879 (1996).
Suzue, K., et al., “Heat Shock Fusion Proteins As Vehicles For Antigen Delivery Into The Major Histocompatibility Complex Class I Presentation Pathway,”Proc. Natl. Acad. Sci. USA 94:13146-13151 (Nov. 1997).
Huang, Q., et al., “In Vivo Cytotoxic T Lymphocyte Elicitation by Mycobacterial Heat Shock Protein 70 Fusion Proteins Maps to a Discrete Domain and Is CD4+T Cell Independent,”J. Exp. Med. 191(2):403-408 (Jan. 17, 2000).
Arrigo, A. and Welch, W.J., “Characterization and Purification of the Small 28,000-Dalton Mammalian Heat Shock Protein,”J. Biol. Chem., 262(32):15359-15369 (1987).
Catelli, M.G., et al., “The common 90-kd protein component of non-transformed ‘8S’ steroid receptors is a heat-shock protein,”EMBO J., 4(12):3131-3135 (1985).
Zylicz, M., et al., “The grpE Protein ofEscherichia coli,”J. Biol. Chem., 262(36):17437-17442 (1987).
Chandrasekhar, G.N., et al., “Purification and Properties of the groES Morphogen

Affiliated with

Also associated with

Rating

In vivo CTL elicitation by heat shock protein fusion... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with In vivo CTL elicitation by heat shock protein fusion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vivo CTL elicitation by heat shock protein fusion... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3397071